Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.7.11.1 (protein kinase)
81,284 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We previously demonstrated that the [Ca2+]i response to PTH is heterogeneous in single UMR-106-01 osteogenic sarcoma cells. To verify whether response heterogeneity is a universal feature of PTH signal transduction, cAMP production was monitored in monolayer cultures of UMR-106-01 cells and human trabecular bone osteoblasts (HOB) using the cAMP-sensitive fluorescent indicator FlCRhR. FlCRhR was microinjected into single cells, and the 500-530/> 560 nm fluorescence ratio was monitored by confocal laserscanning video imaging as a measure of cAMP concentration ([cAMP]). Virtually all UMR-106-01 cells exposed to bovine PTH(1-34) (10(-7) M) exhibited an increase in intracellular [cAMP], with an average fluorescence ratio change of 145 +/- 17% of baseline (n = 15), corresponding to nearly maximal dissociation of protein kinase A. In the continued presence of the hormone (10(-7) M), [cAMP] remained elevated for at least 30 minutes. This effect was accompanied by a slow translocation of the fluorescein-labeled catalytic subunit of protein kinase A from the cytoplasm to the nucleus. In contrast, PTH(1-34) caused no detectable increase in [cAMP] in HOB cells, although PGE2 (3 x 10(-6) M) stimulation was able to increase the FlCRhR ratio (154 +/- 27%, n = 10). The truncated fragment PTH(2-34) was only 67% as potent at PTH(1-34), but deletion of the first two amino acids at the N terminus abolished the hormone's ability to stimulate cAMP production in UMR-106-01 cells. Brief exposure to 10(-7) M of either PTH(3-34) or PTH(7-34) did not affect the amplitude of the fluorescence ratio change induced by equimolar doses of PTH(1-34). Thus, in osteoblast-like cells stimulated with PTH, the [cAMP] response is much more homogeneous from cell to cell than the [Ca2+]i response.
...
PMID:Single-cell analysis of cyclic AMP response to parathyroid hormone in osteoblastic cells. 781 24

Prostaglandins (PGs) may stimulate or inhibit bone cell replication and protein synthesis. These disparities may be concentration or time dependent, or occur in discrete cell types or by different second signals. Cell populations that express progressive degrees of osteoblast-like activity can be obtained by serial collagenase digestion of fetal rat parietal bone. The first (population 1) appears less differentiated, whereas the later (populations 3-5) exhibit biochemical features characteristic of osteoblasts. Within 24 h of treatment, three separate PGs increased DNA synthesis in population 1 with relative potencies of PGE1 < PGE2 < PGF2 alpha. By contrast, PGE1 and PGE2 (both strong cAMP inducers) inhibited basal DNA synthesis in population 3-5. These differences were paralleled by analogous changes in collagen and noncollagen synthesis in each population. The mitogenic effect in population 1 persisted for 72 h, and at later times was sensitive to indomethacin. These changes were unlikely to be cAMP dependent, as PGF2 alpha did not induce cAMP production, and the cAMP inducer forskolin was inhibitory. Moreover, phorbol ester treatment enhanced DNA synthesis to a greater extent in population 1 than in populations 3-5, and cotreatment with H-8 (at Km, approximately 10 microM) and staurosporine (at Km, approximately 0.01 microM) decreased the mitogenic effect of PGs in population 1, consistent with a reduction in protein kinase-C activation. These studies suggest that PGs activate less differentiated bone cells by a protein kinase-dependent event, whereas cAMP (induced by PGE1 and PGE2) decreases DNA and protein synthesis in more differentiated bone cells and tempers the increase in cellular activation found in population 1. Consequently, agents or events that increase the synthesis of specific PGs could differentially regulate, in positive and negative ways, biochemical activities in discrete bone cell populations.
...
PMID:Differential actions of prostaglandins in separate cell populations from fetal rat bone. 792 24

BMY 42393, (2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid), is a new prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 microM). BMY 42393 stimulated platelet adenylate cyclase activity (EC50 = 25 nM), however, the maximal activation was 75-80% of that observed with maximal iloprost or PGE1. Platelets treated with BMY 42393 showed an elevation of cAMP levels and activation of cAMP-dependent protein kinase. BMY 42393 also inhibited thrombin-induced elevation of intracellular free calcium. BMY 42393 competed for radiolabeled iloprost and PGE1 binding to platelet membranes (IC50; 170 nM and 130 nM, respectively); however, it had little effect on radiolabeled PGE2, PGD2, or SQ 29548 binding. These studies indicate that BMY 42393 is a novel platelet aggregation inhibitor which acts by stimulation of platelet prostacyclin receptors to elevate platelet cAMP levels.
...
PMID:2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of action. 802 12

We have previously shown that macrophage-secreted prostaglandins of the E series (PGE) and other agents which increase cAMP inhibit IgM production and proliferation of murine B lymphocytes. In this study, we show that PGE2 inhibits B cell activation events including enlargement, class II MHC hyperexpression, and the expression of the low-affinity receptor for IgE, Fc epsilon RII/CD23 (35-50%) in a cAMP-dependent manner. PGE action is mimicked by other cAMP-inducing agents and is inhibited by RpcAMP (a nonhydrolyzable cAMP analog which is a competitive inhibitor of cAMP-dependent protein kinase A). PGE2 could inhibit enlargement and upregulation of activation Ag even if preincubated with cells and then washed out prior to B cell stimulation. This change in B cell phenotype was abrogated if the reversible protein synthesis inhibitor cycloheximide was included during B cell incubation with PGE2. To identify the newly synthesized cAMP- and PGE-inducible regulatory proteins (PIRP), two-dimensional gel electrophoresis of lysates of B lymphocytes treated +/- PGE2 was performed. This report is the first to identify putative PIRP proteins. The roles of PIRP in PGE regulation of B cell activation and class switching are discussed.
...
PMID:Prostaglandin E2 inhibits B lymphocyte activation by a cAMP-dependent mechanism: PGE-inducible regulatory proteins. 813 Dec 4

In a guinea-pig model we determined the intracellular events mediating the response of duodenal epithelial cells to vasoactive intestinal polypeptide (VIP) and prostaglandin (PG) E2. Intravenous administration of VIP (10(-9) to 10(-7) mol/kg) and PGE2 (10(-9) to 10(-6) mol/kg) dose-dependently increased duodenal epithelial bicarbonate secretion against an HCO3- concentration gradient, measured by a luminal perfusion technique, in anaesthetized guinea-pigs up to 4.5-fold. This secretion could be mimicked by intraduodenal dibutyryl cyclic adenosine monophosphate (dBcAMP; 10(-9) to 10(-7) mol/kg). Secretin (10(-9) mol/kg) and PGF 2 alpha (10(-9) to 10(-7) mol/kg), both given intravenously, were without effect or considerably less efficient. For VIP and PGE2, specific receptors coupled to adenylate cyclase could be demonstrated in homogenates of isolated duodenal epithelial cells. VIP and PGE2 stimulated adenylate cyclase activity up to sixfold, whereas PGF2 alpha and secretin were considerably less potent and efficient. VIP and PGE2 increased intracellular cyclic AMP levels up to fivefold and ninefold, respectively. This was followed by an increase in cytosolic protein kinase A activity. Bicarbonate secretion was maximal at 30 min. Examination of the subcellular distribution of protein kinase A showed a predominant cytosolic location. These data support the notion the PGE2 and VIP cause bicarbonate secretion by the serial activation of adenylate cyclase and protein kinase A in duodenal epithelial cells.
...
PMID:Cyclic adenosine monophosphate is the second messenger of prostaglandin E2- and vasoactive intestinal polypeptide-stimulated active bicarbonate secretion by guinea-pig duodenum. 817 Dec 84

When endometrial stromal cells from rat uteri sensitized for the decidual cell reaction are cultured in vitro, they undergo decidualization, as indicated by increased alkaline phosphatase (ALP) activity. Prostaglandin E2 (PGE2) stimulates this increase in activity. To determine the role of cAMP in the stimulation, we examined the effect of 2':5'-dideoxyadenosine (DDA), an inhibitor of adenylate cyclase, on the ability of PGE2 to increase ALP activity. As indicated by [3H]cAMP accumulation in endometrial stromal cells preincubated with [3H]adenine, DDA inhibited PGE2-stimulated synthesis of cAMP in a concentration-dependent manner. Furthermore, DDA caused a significant decrease in the PGE2-induced ALP activity on day 3 of culture. Dibutyryl cAMP overrode this inhibition. The effect of DDA was not mimicked by adenosine, which had a stimulatory effect on ALP activity in the non-stimulated cultures and no significant effect in PGE2-stimulated cultures. Thus the inhibitory effect of DDA on PGE2-stimulated ALP activity is unlikely to be mediated by adenosine-related receptors. These results suggest that cAMP is an essential, but not necessarily the only, intracellular messenger of PGE2 in endometrial stromal cells during decidualization. The isozymes of cAMP-dependent protein kinase (PKA) mediating the effect of cAMP were assessed by using cAMP analogues directed at selective sites of PKA isozymes. Synergistic activation of ALP activity in endometrial stromal cells by pairs of analogues directed at types I and II PKA suggested that both types were functionally important during decidualization.
...
PMID:Prostaglandin E2, cAMP and cAMP-dependent protein kinase isozymes during decidualization of rat endometrial stromal cells in vitro. 821 Apr 42

Treatment of macrophages with zymosan, 4 beta-phorbol 12-myristate 13-acetate (PMA) and fluoride but not with A 23187 or arachidonic acid (delta Ach) leads to a generation of diacylglycerol (acyl2Gro). Formation of inositol phosphates is achieved with zymosan, only. An elevation of intracellular calcium is obtained with zymosan and A 23187 but not with PMA, fluoride or delta Ach. Prior treatment of the cells with phorbol ester for 3 h which has been shown recently to result in a down-regulation of protein kinase (PK) C-beta but not PKC-delta [Duyster, J., Schwende, H., Fitzke, E., Hidaka H. & Dieter P. (1993) Biochem. J. 292, 203-207] has no effect on the zymosan-induced formation of acyl2Gro or inositol phosphates but inhibits the PMA-induced generation of acyl2Gro. Down-regulation of PKC-delta by prior phorbol ester treatment for 24 h augments the zymosan-induced generation of acyl2Gro and inositol phosphates. The acyl2Gro lipase inhibitor RG 80267 inhibits the PMA-induced and fluoride-induced generation of prostaglandin (PG) E2, reduces the zymosan-induced release of PGE2 by 50% but has no effect on PGE2 formation of unstimulated, A 23187-treated or delta Ach-treated cells. Furthermore, RG 80267 enhances accumulation of delta Ach-labeled acyl2Gro in response to zymosan, PMA and fluoride. These data indicate that zymosan activates a phosphatidylinositol 4,5-bisphosphate-specific phospholipase (PL) C, that generation of acyl2Gro by PMA and fluoride occurs via hydrolysis of other phospholipids, that PKC-beta is involved in the PMA-induced generation of acyl2Gro and PKC-delta negatively modulates the zymosan-induced activation of PLC and PMA and fluoride induce a liberation of delta Ach from acyl2Gro, A 23187 activates the PLA2 pathway and zymosan stimulates both, the acyl2Gro- and PLA2-pathway.
...
PMID:Formation of diacylglycerol, inositol phosphates, arachidonic acid and its metabolites in macrophages. 826 66

Interleukin-1 (IL-1) is known to be a potent stimulator of bone resorption. The effect of IL-1 has been shown to be mediated, at least in part, by IL-1-induced prostaglandin (PG) E2 production in osteoblasts. The intracellular signal transduction mechanism of IL-1 in the PG production, however, is unknown. In the present study using a mouse osteoblastic cell line, MC3T3-E1 (MC), the possible involvement of two representative signal transduction pathways, protein kinase A (PKA) or protein kinase C (PKC)-dependent pathway in the IL-1 alpha stimulated PGE2 production, was investigated. MC produced PGE2 30 min after the IL-1 stimulation. This was inhibited with cycloheximide, suggesting the involvement of de novo protein synthesis. The IL-1-induced PGE2 production was inhibited by H-7 in a dose dependent manner. Since H-7 is known to inhibit PKA as well as PKC, a more specific inhibitor of PKA KT5720 or staurosporin was used to determine the respective role of PKA or PKC in the production of PGE2. KT5720 inhibited the IL-1-induced PGE2 production in MC in a dose dependent fashion. Similarly, staurosporin inhibited the IL-1-induced PGE2 production in MC in a dose dependent manner. The effect of the activity of PKA or PKC on the production of PGE2 was also investigated. A stimulator of PKA, 8-bromoadenosine 3'5'-cyclicmonophosphate (8-Br-cAMP), as well as a stimulator of PKC phorbol 12-myristate 13-acetate (PMA) induced PGE2 production in MC. The effect of these agents on the PGE2 production was additive.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Intracellular mechanism of interleukin-1 alpha-induced prostaglandin E2 (PGE2) production in a mouse osteoblast-like cell line and the possible involvement of protein kinase A and protein kinase C]. 828 36

Sulindac suppresses the growth of colon polyps in Gardner syndrome and familial adenomatous polyposis. The mechanism of action is not known. The problems are to ascertain the significance of high prostaglandin concentrations in transformed cells, colon polyps and cancers and to explain how sulindac restores normal growth patterns. A few clinical observations and an abundance of experimental data can be integrated to produce a reasonable model based on current biochemical and physiologic concepts. A fundamental defect in the formation of colon polyps is mutation of the APC (adenomatous polyposis coli) gene that leads to inadequate suppression of proliferation. There is high PGE2 content in colon polyps and cancers, presumably the result of stimulation by protein kinase C (PKC). In small quantities it stimulates cyclic AMP production but with persistent high concentrations it desensitizes and down-regulates specific PG receptors and inactivates adenylate cyclase, cAMP synthesis, and the cAMP-dependent mechanism for control of proliferation. The PKC pathway is thereby unopposed. It is hypothesized that restriction of PG synthesis by sulindac is accompanied by resensitization of PG receptors, and reactivation of the cAMP-dependent pathway for control of cell growth. It is further postulated that restoration of cAMP synthesis and protein kinase A activity converts a functionally inadequate mutant APC suppressor gene to one sufficient to inhibit colon polyp formation.
...
PMID:The effect of sulindac on colon polyps: circumvention of a transformed phenotype--a hypothesis. 828 54

We recently reported a novel intracellular mechanism of renal Na-K-ATPase regulation by agents that increase cell cAMP, which involves protein kinase A-phospholipase A2 and is mediated by one or more arachidonic acid metabolites (Satoh, T., H. T. Cohen, and A. I. Katz. 1992. J. Clin. Invest. 89:1496). The present studies were, therefore, designed to assess the role of eicosanoids in the modulation of Na-K-ATPase activity in the rat cortical collecting duct. The effect of various cAMP agonists (dopamine, fenoldopam, vasopressin, forskolin, and dibutyryl cAMP), which inhibited the pump to a similar extent (approximately 50%), was independent of altered Na entry as it was elicited in the presence of amiloride or nystatin, or when NaCl was replaced with choline Cl. This effect was completely blocked by SKF 525A or ethoxyresorufin, two inhibitors of the cytochrome P450-dependent monooxygenase pathway, or by pretreating the animals with CoCl2, which depletes cytochrome P450. Equimolar concentrations (10(-7) M) of the cyclooxygenase inhibitors indomethacin or meclofenamate caused only a partial inhibition of the cAMP agonists' effect on the pump, whereas nordihydroguaiaretic acid or A 63162, two inhibitors of the lipoxygenase pathway, were without effect. Furthermore, two products of this pathway, leukotriene B4 and leukotriene D4, had no effect on Na-K-ATPase activity, and ICI 198615, a leukotriene receptor antagonist, did not alter pump inhibition by cAMP agonists. Several P450 monoxygenase arachidonic acid metabolites (5,6-epoxyeicosatrienoic acid; 11,12-epoxyeicosatrienoic acid; 11,12-dihydroxyeicosatrienoic acid; and 12(R)-hydroxyeicosatetraenoic acid) as well as PGE2 inhibited the Na:K pump in dose-dependent manner, but the effect of PGE2 was blocked when Na availability was altered, whereas that of 12(R)-HETE remained unchanged. We conclude that the cytochrome P450-monooxygenase pathway of the arachidonic acid cascade plays a major role in the modulation of Na:K pump activity by eicosanoids in the rat cortical collecting duct, and that products of the cyclooxygenase pathway may contribute to pump inhibition indirectly, by decreasing intracellular Na.
...
PMID:Intracellular signaling in the regulation of renal Na-K-ATPase. II. Role of eicosanoids. 838 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---